Clinical research of individualized therapy in advanced esophageal cancer based on the ERCC1 C8092A genotype

Yao,Yi‑Wei; He,Yi‑Fu; Han,Xing‑Hua; Ji,Chu‑Shu; Hu,Bing

doi:10.3892/ol.2018.8894

Clinical research of individualized therapy in advanced esophageal cancer based on the ERCC1 C8092A genotype

Authors:
- Yi‑Wei Yao
- Yi‑Fu He
- Xing‑Hua Han
- Chu‑Shu Ji
- Bing Hu
View Affiliations

Affiliations: Department of Medical Oncology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, P.R. China
Published online on: June 4, 2018 https://doi.org/10.3892/ol.2018.8894
Pages: 2539-2548

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the role and clinical value of the detection of Excision repair cross‑complementing 1(ERCC1) C8092A polymorphisms in individualized therapy of patients with advanced esophageal cancer. A total of 127 patients with advanced esophageal cancer were enrolled between January 2010 and January 2014 in Anhui Provincial Hospital. Patients were randomly assigned in a 1:2 ratio to a standard treatment group or an individualized treatment group, respectively, prior to ERCC1 C8092A assessment. Patients in the standard treatment group were treated with paclitaxel and cisplatin. The DNA was obtained from the peripheral blood of individualized treatment patients, amplified by PCR and sequenced to determine the ERCC1 C8092A polymorphism prior to the administration of chemotherapies. Patients with the ERCC1 C8092A genotype of A/A or A/C received paclitaxel and cisplatin, and those with the genotype of C/C received paclitaxel and fluorouracil. The primary endpoint was response rate (RR). The secondary endpoints included toxicity of chemotherapy, progression‑free survival (PFS) and overall survival (OS) times. Differences between the groups were evaluated by χ2 test. Differences in survival were analyzed by Kaplan‑Meier survival curves. The survival rate was analyzed by log‑rank test. Follow‑up data was obtained until December 2015. The RR was obtained for 15 patients (34.8%) in the standard treatment group and 45 patients (53.6%) in the individualized treatment group (χ2=3.095; P=0.046). For adverse events, nausea and vomiting and anemia were significantly decreased in the individualized treatment group compared with the standard treatment group (P=0.001 and P=0.004, respectively). The median progression free survival time was 4.4 months [95% confidence interval (CI)3.8‑5.0 months] in the standard treatment group and 6.6 months (95% CI, 5.8‑7.4 months) in the individualized treatment group (P=0.018). The median overall survival time was 11.4 months (95% CI, 10.1‑12.7 months) in the standard treatment group and 14.2 months (95% CI, 13.2‑15.2 months) in the individualized treatment group (P=0.008). The RR, toxicity of chemotherapy, PFS and OS were significantly improved in the individualized treatment group compared with the standard treatment group. Detection of ERCC1 gene polymorphisms maybe performed for patients with advanced esophageal cancer to improve individualized therapy, which requires additional study.

View Figures

View References

1	Hao J and Shao K: The epidemiology, current status of management, challenge and future strategy for esophageal cancer in China. China Oncol. 21:501–504. 2011.
2	Domper Arnal MJ, Ferrández Arenas Á and Lanas Arbeloa Á: Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 21:7933–7943. 2015. View Article : Google Scholar : PubMed/NCBI
3	Okada E, Ukawa S, Nakamura K, Hirata M, Nagai A, Matsuda K, Ninomiya T, Kiyohara Y, Muto K, Kamatani Y, et al: Demographic and lifestyle factors and survival among patients with esophageal and gastric cancer: The Biobank Japan Project. J Epidemiol. 27:(Suppl):. S29–S35. 2017. View Article : Google Scholar : PubMed/NCBI
4	Xiang K and Fan Q: Progress in medication treatment of esophageal cancer. World J Gastroenterol. 20:3482–3487. 2012.
5	National Comprehensive Cancer Network (NCCN): NCCN. Fort Washington, PA; https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdfDecember 14–2009
6	Nakamura T, Takahashi M, Niigata R, Yamashita K, Kume M, Hirai M and Yasui H: Changes in blood concentrations of trace metals in cancer patients receiving cisplatin-based chemotherapy. Biomed Rep. 5:737–744. 2016. View Article : Google Scholar : PubMed/NCBI
7	Sun H, Qin TJ, Ruan ZP, Wang H and Ma Y: Clinical study of vinorelbine combined with cisplatin in the treatment of advanced esophageal cancer. Cancer Res Prevent Treatment. 33:682–685. 2006.(In Chinese).
8	Chen J, He Y, Hu B, Ji CS, Hu CL and Fan PS: Prognostic value of the ERCC1 and TS genetic polymorphisms in advanced esophageal cancer treated with Cisplatin/fluorouracil chemotherapy. Tumor. 4:314–321. 2010.
9	Ryu H, Song IC, Choi YS, Yun HJ, Jo DY, Kim JM, Ko YB and Lee HJ: ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy. Medicine (Baltimore). 96:e94022017. View Article : Google Scholar : PubMed/NCBI
10	Palomba G, Atzori F, Budroni M, Ombra M, Cossu A, Sini M, Pusceddu V, Massidda B, Frau B and Notari F: ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. J Transl Med. 12:2722014. View Article : Google Scholar : PubMed/NCBI
11	Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW and Christoph DC: ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: Resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer. 14:558–567.e3. 2013. View Article : Google Scholar : PubMed/NCBI
12	Chen C, Wang F, Wang Z, Li C, Luo H, Liang Y, An X, Shao J and Li Y: Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 72:315–322. 2013. View Article : Google Scholar : PubMed/NCBI
13	Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L and Moore KN: The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol. 130:377–382. 2013. View Article : Google Scholar : PubMed/NCBI
14	Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V and Mavroudis D: DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 10:118–123. 2009. View Article : Google Scholar : PubMed/NCBI
15	Bradbury PA, Marshall AL, Kulke AH, et al: Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer. J Clin Oncol (ASCO Annual Meeting). 25:25112007.
16	Shan B, He Y, Chen J, Li XQ, Ji CS, Hu CL and Hu B: Clinical outcome of advanced esophageal cancer treated with cisplatin influenced by ERCC1 gene polymorphism in peripheral blood. Chin J Cancer Prevention Treatment. 18:1447–1450. 2010.
17	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC cancer staging manual. 7th edition. Springer-Verlag; New York, NY; pp. 103–15. 2009
18	Rice TW, Blackstone EH and Rusch VW: 7th edition of the AJCC cancer staging manual: Esophagus and esophagogastric junction. Ann Surg Oncol. 17:1721–1724. 2010. View Article : Google Scholar : PubMed/NCBI
19	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
20	National Cancer Institute (NCI): Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfJune 14–2010
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Stoter G and van der Gaast A: Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer. 89:2045–2050. 2003. View Article : Google Scholar : PubMed/NCBI
23	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
24	Seiwert TY, Wang X, Heitmann J, Villegas-Bergazzi V, Sprott K, Finn S, O'Regan E, Farrow AD, Weichselbaum RR, Lingen MW, et al: DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 9:e1021122014. View Article : Google Scholar : PubMed/NCBI
25	Benhamou S and Sarasin A: Variability in nucleotide excision repair and cancer risk: A review. Mutat Res. 462:149–158. 2000. View Article : Google Scholar : PubMed/NCBI
26	Benhamou S and Sarasin A: ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis. 17:463–469. 2002. View Article : Google Scholar : PubMed/NCBI
27	Gregg SQ, Robinson AR and Niedernhofer LJ: Physiological consequences of defects in ERCC1-XPF DNA repair endonuclease. DNA Repair (Amst). 10:781–791. 2011. View Article : Google Scholar : PubMed/NCBI
28	Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, Kasemsarn C and Patumanond J: The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: Tumor recurrence and overall survival. Cancer Manag Res. 5:327–336. 2013. View Article : Google Scholar : PubMed/NCBI
29	Reed E, Dabholkar M, Thornton K, Thompson C, Yu JJ and Bostick-Bruton F: Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncol Rep. 7:1123–1128. 2000.PubMed/NCBI
30	Wood RD: DNA repair in eukaryotes. Annu Rev Biochem. 65:135–167. 1996. View Article : Google Scholar : PubMed/NCBI
31	Vogel U, Dybdahl M, Frentz G and Nexo BA: DNA repair capacity: Inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res. 461:197–210. 2000. View Article : Google Scholar : PubMed/NCBI
32	Wang J, Zhou XQ, Li JY, Cheng JF, Zeng XN, Li X and Liu P: Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer. Chin J Cancer Res. 26:323–330. 2014.PubMed/NCBI
33	Wang Y, Chen J, Li X, He Y, Hu B, Ji C and Xu J: Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma. Oncol Rep. 25:1047–1052. 2011.PubMed/NCBI
34	Kim M, Ku JH, Kwak C, Kim HH, Lee E, Keam B, Kim TM, Heo DS, Lee SH and Moon KC: Predictive and prognostic value of ribonucleotide reductase regulatory Subunit M1 and excision repair Cross-complementation group 1 in advanced urothelial carcinoma (UC) treated with first-line gemcitabine plus platinum combination chemotherapy. PLoS One. 10:e01333712015. View Article : Google Scholar : PubMed/NCBI
35	Frischknecht L, Meerang M, Soltermann A, Stahel R, Moch H, Seifert B, Weder W and Opitz I: Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. J Thorac Cardiovasc Surg. 149:1539–1546.e1. 2015. View Article : Google Scholar : PubMed/NCBI
36	Schena M, Guarrera S, Buffoni L, Salvadori A, Voglino F, Allione A, Pecorari G, Ruffini E, Garzino-Demo P, Bustreo S, et al: DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. DNA Repair (Amst). 11:374–380. 2012. View Article : Google Scholar : PubMed/NCBI
37	Hossain M, Banik NL and Ray SK: Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int. 61:1102–1113. 2012. View Article : Google Scholar : PubMed/NCBI
38	Chao YK, Wu YC, Liu YH, Tseng CK, Chang HK, Hsieh MJ, Chu Y and Liu HP: Distant nodal metastases from intrathoracic esophageal squamous cell carcinoma: Characteristics of long-term survivors after chemoradiotherapy. J Surg Oncol. 102:158–162. 2010. View Article : Google Scholar : PubMed/NCBI
39	Zhang X, Shen L, Li J, Li Y, Li J and Jin M: A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol. 31:29–33. 2008. View Article : Google Scholar : PubMed/NCBI
40	Yun T, Han JY, Lee JS, Choi HL, Kim HY, Nam BH and Kim HT: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC Cancer. 11:3852011. View Article : Google Scholar : PubMed/NCBI
41	Matsumoto H, Kubota H, Higashida M, Yoden E, Hiratsuka J, Haruma K, Nakamura M and Hirai T: Docetaxel/TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus-a phase II trial. Anticancer Res. 34:3759–3763. 2014.PubMed/NCBI
42	Schnirer II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, Roth JA and Ajani JA: Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 24:91–95. 2001. View Article : Google Scholar : PubMed/NCBI